Evaluation and management of galactorrhea

American Family Physician

Volumn 85, Issue 11, 2012, Pages 1073-1080

  Huang, Wenyu ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CABERGOLINE; COCAINE; CREATININE; ESTROGEN; GONADOTROPIN; LUTEINIZING HORMONE; METHYLDOPA; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OPIATE; PROLACTIN; RESERPINE; TESTOSTERONE; THYROTROPIN; VERAPAMIL;

ARTICLE; BONE DENSITY; BRAIN DAMAGE; BREAST DISCHARGE; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DROWSINESS; DRUG MEGADOSE; ESTROGEN THERAPY; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOTHYROIDISM; KIDNEY FAILURE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PHYSICAL EXAMINATION; PREGNANCY; PROLACTINOMA; THORAX WALL DEFECT; VALVULAR HEART DISEASE; VOMITING;

EID: 84861897515     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kleinberg DL. Endocrinology of mammary development, lactation and galactorrhea. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. London, United Kingdom: W.B. Saunders; 2000:2464-2475.
2. Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148 (3):325-331.
3. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am. 2001;30(3):585-610.
4. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000; 80 (4):1523-1631.
5. van den Pol AN. Excitatory neuromodulator reduces dopamine release, enhancing prolactin secretion. Neuron. 2010;65 (2):147-149.
6. Morel GR, Carón RW, Cónsole GM, et al. Estrogen inhibits tuberoinfundibular dopaminergic neurons but does not cause irreversible damage. Brain Res Bull. 2009;80(6): 347-352.
7. Molitch ME. Pituitary disorders during pregnancy. Endo-crinol Metab Clin North Am. 2006;35(1):99-116, vi.
8. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353(3):275-285.
9. Vaidyanathan L, Barnard K, Elnicki DM. Benign breast disease: when to treat, when to reassure, when to refer. Cleve Clin J Med. 2002;69(5):425-432.
10. Leung AK, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician. 2004;70(3):543-550.
11. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006; 65(2):265-273.
12. Peña KS, Rosenfeld JA. Evaluation and treatment of galactorrhea. Am Fam Physician. 2001; 63 (9):1763-1770.
13. Melmed S, Kleinberg DL. Anterior pituitary. In: Kronen-berg H, Williams RH, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, Pa.: Elsevier Saunders; 2007:155-262.
14. Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyper-prolactinaemia need re-defnition? A study of 226 patients with histologically verifed non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 2006; 65(4):524-529.
15. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003;349(21):2035-2041.
16. Klibanski A. Clinical practice. Prolactinomas [published correction appears in N Engl J Med. 2010;362(22): 2142]. N Engl J Med. 2010;362(13):1219-1226.
17. Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery. 1998; 42(4):913-916.
18. Katznelson L, Kleinberg D, Vance ML, et al. Hypogonad-ism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study [published correction appears in Clin Endocrinol (Oxf). 2001;55(5):699]. Clin Endocrinol (Oxf). 2001;54(2):183-188.
19. Lyons DJ, Horjales-Araujo E, Broberger C. Synchronized network oscillations in rat tuberoinfundibular dopa-mine neurons: switch to tonic discharge by thyrotropin-releasing hormone. Neuron. 2010;65(2):217-229.
20. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2003;2(1):23-32.
21. Saha MT, Saha HH, Niskanen LK, Salmela KT, Pasternack AI. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron. 2002; 92(3):735-737.
22. Molitch ME. Drugs and prolactin. Pituitary. 2008; 11 (2): 209-218.
23. Coker F, Taylor D. Antidepressant-induced hyperpro-lactinaemia: incidence, mechanisms and management. CNS Drugs. 2010;24(7):563-574.
24. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050-1057.
25. Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry. 2010;10:26.
26. Cooper O, Geller JL, Melmed S. Ovarian hyperstimu-lation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab. 2008;4(4): 234-238.
27. Christin-Maître S, Delemer B, Touraine P, Young J. Pro-lactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris). 2007;68(2-3):106-112.
28. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169(6): 575-581.
29. Chahal J, Schlechte J. Hyperprolactinemia. Pituitary. 2008;11(2):141-146.
30. Berinder K, Stackenäs I, Akre O, Hirschberg AL, Hult-ing AL. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf). 2005;63(4):450-455.
31. Mancini T, Casanueva FF, Giustina A. Hyperprolac-tinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008;37(1):67-99, viii.
32. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
33. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27(5):485-534.
34. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comor-bidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzap-ine. Psychoneuroendocrinology. 2006;31(5):577-588.
35. Molitch ME. Prolactinomas and pregnancy. Clin Endo-crinol (Oxf). 2010;73(2):147-148.
36. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smer-aldi E. Cabergoline treatment of risperidone-induced hy p erprolactinemia: a pilot stud y. J Clin Psychiatry. 2004; 65(2):187-190.
37. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med. 1992; 37(8):737-740.